International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cytarabine
  • Leukemia, Myeloid, Acute

abstract

  • Neither elacytarabine nor any of the seven alternative treatment regimens provided clinically meaningful benefit to these patients. OS in both study arms and for all treatments was extremely poor. Novel agents, novel clinical trial designs, and novel strategies of drug development are all desperately needed for this patient population.

publication date

  • June 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.52.8562

PubMed ID

  • 24841975

Additional Document Info

start page

  • 1919

end page

  • 26

volume

  • 32

number

  • 18